Renal Cell Carcinoma

CHICAGO — In renal cell carcinoma, adjuvant everolimus improved recurrence-free survival after nephrectomy but narrowly missed the benchmark for statistical significance, according to final results from the phase 3 EVEREST study.

In this video Nancy Moldawer, RN, MSN, discussed strategies for educating nurses to keep patients with renal cell carcinoma on appropriate therapies, which were explored at ONS Congress 2022.

In this video, Nancy Moldawer, RN, MSN, discussed new treatments in kidney cancer and how to apply nursing strategies to best meet the needs of patients with renal cell carcinoma.

A novel PD-1/CTLA-4 bispecific checkpoint inhibitor demonstrated antitumor activity and tolerability among patients with advanced solid tumors, according to study results.

Current and extended durations of non-aspirin use appeared associated with an increased risk for fatal renal cell carcinoma, according to study results.

Mark W. Ball, MD, spoke with Healio about an ongoing phase 2 study assessing the use of cytoreductive stereotactic hypofractionated radiotherapy along with ipilimumab and nivolumab in patients with metastatic renal cell carcinoma.

In this video, Sumanta K. Pal, MD, discusses updates from a clinical trial on the use of nivolumab/ipilimumab with and without a probiotic agent in patients with metastatic renal cell carcinoma.

Sumanta K. Pal, MD, co-director of Kidney Cancer Program at City of Hope, and a HemOnc Today Editorial Board Member, spoke with Healio about studies on renal cell carcinoma presented at the 2022 ASCO Genitourinary Cancers Symposium.

In this video, Mark W. Ball, MD, discusses the ongoing SWOG S1931 study assessing the use of immune checkpoint inhibitors with or without cytoreductive nephrectomy in patients with renal cell carcinoma.

In this video, Mark W. Ball, MD, discusses updates from the KEYNOTE-564 study on the use of adjuvant pembrolizumab in certain patients with renal cell carcinoma presented at the 2022 ASCO Genitourinary Cancers Symposium.